Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00451191
Other study ID # MIST2
Secondary ID U01DK060817
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2006
Est. completion date December 2009

Study information

Verified date April 2020
Source National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a double-blind randomized phase II trial to determine whether two different doses of BoNT/A injection into the prostate gland demonstrate sufficient improvement in the management of lower urinary symptoms due to BPH to warrant more extensive research. Subjects will receive either a 100U or 300U dose. Participation will last 1 year.


Other known NCT identifiers
  • NCT00395525

Recruitment information / eligibility

Status Completed
Enrollment 134
Est. completion date December 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender Male
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Male at least 50 years of age.

- Voided volume => 125 ml.

- Maximum urinary flow < 15 ml/sec.

- AUA symptom severity score => 8.

- Patient signed informed consent prior to the performance of any study procedures.

- Patient able to complete the study protocol in the opinion of the investigator.

Exclusion Criteria:

- Any prior surgical intervention for BPH.

- Current diagnosis of acute or chronic prostatitis (which may cause LUTS that mimic BPH).

- Overactive bladder without bladder outlet obstruction.

- Enrolled in another treatment trial for any disease within the past 30 days.

- Men interested in future fertility.

- Previous exposure to botulinum toxin.

- On alpha-blocker within the past 48 hours.

- On any 5-alpha-reductase inhibitor within the past month.

- Post void residual > 350 ml.

- On phenylephrine, pseudoephedrine, imipramine, an anticholinergic, or cholinergic medication within the past 2 weeks.

- On estrogen, androgen, any drug producing androgen suppression, or anabolic steroids within the past 4 months.

- Clinically significant renal or hepatic impairment as determined by abnormal creatinine or AST levels (based on local institutional values).

- Serum prostate specific antigen level > 8 ng/ml (Hybritech). For those with a PSA between 4-8 ng/ml, the PSA elevation must be considered to be from a benign cause in the opinion of the PI. This decision can be based on PSA velocity, previous TRUS biopsy, percent free PSA, or other clinical estimations in keeping with sound urologic care.

- Active urinary tract disease or biopsy of the prostate within the past 6 weeks.

- Daily use of a pad or device for incontinence required.

- Episode of unstable angina pectoris, myocardial infarction, transient ischemic attack, or cerebrovascular accident (stroke) within the past 6 months.

- On aminoglycosides or any drug that interfere with neuromuscular transmission.

- Eaton-Lambert syndrome, hemophilia, hereditary clotting factors deficiency, or bleeding diathesis.

- Penile prosthesis or artificial urinary sphincter.

- History or current evidence of carcinoma of the prostate or bladder, pelvic radiation or surgery, urethral stricture, or bladder neck obstruction.

- Known primary neurologic conditions such as multiple sclerosis, myasthenia gravis or Parkinson's disease, or other neurological diseases known to affect bladder function.

- Documented bacterial or acute prostatitis within the past year.

- Two documented urinary tract infections of any type in the past year (UTI defined as > 100,000 colonies per ml urine from midstream clean catch or catheterized specimen).

- History of bladder calculi.

- Patients must be off aspirin, NSAIDS, and Coumadin for 7 or more days prior to botulinum toxin injection.

- Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years).

- Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, hypersensitivity to botulinum toxin or anesthetics used in the study, syncope, uncontrolled diabetes.

Study Design


Intervention

Drug:
botulinum toxin type A (BoNT/A)
100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.

Locations

Country Name City State
United States Northwestern University Chicago Illinois
United States University of Texas Southwestern Medical Center Dallas Texas
United States University of Colorado Health Sciences Center Denver Colorado
United States Baylor College of Medicine Houston Texas
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Cornell University New York New York
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) George Washington University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, Mynderse LA, Roehrborn CG, Smith CP, Bruskewitz R. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomize — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in the AUA Symptom Score Index by 30% From Baseline Within the First 12 Weeks After Injection. The primary outcome was treatment success at 3 months post-treatment, defined as (1) improvement in the AUASI by at least 30% and/or (2) Qmax improvement of more than 30%, each determined from baseline to 3 months after injection. In addition, two safety criteria also had to be met; a dose failed if (1) any reported event was determined to be related to the onabotulinum toxin A injection and was considered life threatening, disabling, or fatal or (2) >=40% of the participants reported a moderate or severe side effect related to the botulinum toxin injection. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A